Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Corcept Therapeutics Incorporated

Healthcare US CORT

33.54USD
-0.45(1.32%)

Last update at 2026-03-10T20:27:00Z

Day Range

32.9334.00
LowHigh

52 Week Range

20.8434.27
LowHigh

Fundamentals

  • Previous Close 33.99
  • Market Cap3290.98M
  • Volume995477
  • P/E Ratio26.12
  • Dividend Yield-%
  • EBITDA122.80M
  • Revenue TTM523.53M
  • Revenue Per Share TTM5.12
  • Gross Profit TTM 396.47M
  • Diluted EPS TTM1.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 116.19M 125.01M 131.60M 116.68M 92.15M
Minority interest - - - - -
Net income 101.42M 112.51M 106.01M 94.18M 75.41M
Selling general administrative 152.85M 122.36M 105.33M 100.36M 81.29M
Selling and marketing expenses - - - - -
Gross profit 396.47M 360.70M 348.29M 300.98M 246.03M
Reconciled depreciation 2.97M 3.07M 2.24M 2.17M 0.24M
Ebit 109.67M 121.41M 125.97M 109.44M 89.26M
Ebitda 112.63M 124.48M 128.20M 111.61M 89.50M
Depreciation and amortization 2.97M 3.07M 2.24M 2.17M 0.24M
Non operating income net other - 0.53M 3.40M 5.07M 2.66M
Operating income 112.63M 124.48M 128.20M 111.61M 89.50M
Other operating expenses 289.22M 241.50M 225.67M 194.88M 161.75M
Interest expense 3.56M 3.60M 5.64M 5.07M 2.66M
Tax provision 14.77M 12.49M 25.59M 22.50M 16.74M
Interest income 3.56M 0.53M 3.40M 5.07M 2.66M
Net interest income 3.56M 0.53M 3.40M 5.07M 2.66M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.77M 12.49M 25.59M 22.50M 16.74M
Total revenue 401.86M 365.98M 353.87M 306.49M 251.25M
Total operating expenses 283.84M 236.22M 220.09M 189.38M 156.54M
Cost of revenue 5.38M 5.28M 5.58M 5.50M 5.21M
Total other income expense net 3.56M 0.53M 3.40M 5.07M 2.66M
Discontinued operations - - - - -
Net income from continuing ops 101.42M 112.51M 106.01M 94.18M 75.41M
Net income applicable to common shares 101.29M 112.51M 106.01M 94.18M 75.41M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 621.52M 583.43M 423.76M 571.73M 412.31M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 27.56M 16.42M 10.31M 6.70M 6.04M
Total liab 114.81M 81.59M 47.95M 48.39M 41.13M
Total stockholder equity 506.70M 501.84M 375.81M 523.34M 371.18M
Deferred long term liab - - - - -
Other current liab 0.65M 68.47M -0.52600M -2.05000M 30.13M
Common stock 0.13M 0.13M 0.13M 0.12M 0.12M
Capital stock 0.13M 0.13M 0.13M 0.12M 0.12M
Retained earnings 402.53M 296.39M 194.97M 82.46M -23.55500M
Other liab - 9.10M 0.41M 0.40M 0.39M
Good will - - - - -
Other assets - 77.45M 43.50M 52.85M 61.11M
Cash 135.55M 436.62M 335.81M 476.89M 315.31M
Cash and equivalents - - - - -
Total current liabilities 104.50M 81.59M 6.91M 10.55M 41.13M
Current deferred revenue 86.30M - - - -
Net debt -135.40000M -435.47600M -335.28600M -474.34100M -311.85300M
Short term debt 0.15M 1.14M 0.53M 2.05M 3.46M
Short long term debt - - - - -
Short long term debt total 0.15M 1.14M 0.53M 2.55M 3.46M
Other stockholder equity 103.44M 206.19M 180.94M 440.35M 394.36M
Property plant equipment - 1.78M 1.00M 1.68M 1.05M
Total current assets 458.64M 498.71M 381.39M 524.25M 352.65M
Long term investments 57.18M 4.95M 112.28M 36.20M 39.35M
Net tangible assets - 501.84M 375.81M 523.34M 371.18M
Short term investments 232.67M 365.34M 145.92M 364.51M 244.69M
Net receivables 55.12M 45.06M 27.62M 26.20M 19.93M
Long term debt - - - - -
Inventory 7.73M 17.03M 17.95M 21.16M 17.41M
Accounts payable 17.40M 11.98M 6.91M 10.55M 7.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.61M -0.86900M -0.22700M 0.41M 0.26M
Additional paid in capital - - - - -
Common stock total equity - - 0.13M 0.12M 0.12M
Preferred stock total equity - - - - -
Retained earnings total equity - - 194.97M 82.46M -23.55500M
Treasury stock - - - - -62.70400M
Accumulated amortization - - - - -
Non currrent assets other 14.79M 17.17M 14.40M 13.37M 10.54M
Deferred long term asset charges - - - - -
Non current assets total 162.88M 84.72M 42.37M 47.48M 59.66M
Capital lease obligations 0.15M 1.14M 0.53M 2.55M 3.46M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -114.32700M 136.59M -118.02500M -116.74000M -90.46900M
Change to liabilities 4.76M 1.63M 8.32M 1.85M 6.17M
Total cashflows from investing activities -114.32700M 136.13M -119.26300M -117.82800M -90.76700M
Net borrowings - - - - -
Total cash from financing activities -17.28400M -302.59100M 12.21M -28.64500M -14.33500M
Change to operating activities -5.19600M 1.51M 1.25M -0.71500M 14.14M
Net income 101.42M 112.51M 106.01M 94.18M 75.41M
Change in cash -11.28800M 1.43M 44.92M -10.35600M 10.56M
Begin period cash flow 77.62M 76.19M 31.27M 41.62M 31.06M
End period cash flow 66.33M 77.62M 76.19M 31.27M 41.62M
Total cash from operating activities 120.32M 167.89M 151.97M 136.12M 115.67M
Issuance of capital stock - - - - -
Depreciation 2.97M 3.07M 2.24M 2.17M 0.24M
Other cashflows from investing activities - - - -116.74000M -90.46900M
Dividends paid - - - - -
Change to inventory 1.20M 3.44M -3.51400M -1.04400M -7.77900M
Change to account receivables -3.43200M -1.42700M -6.27000M -2.34000M -2.28800M
Sale purchase of stock 0.00000M -295.98500M -9.94500M -30.97500M -23.65700M
Other cashflows from financing activities -21.66500M -6.60600M 22.16M 2.33M 9.32M
Change to netincome 9.92M 47.29M 47.78M 46.19M 37.81M
Capital expenditures 0.41M 0.47M 1.24M 1.09M 0.30M
Change receivables - -1.42700M -6.27000M -2.34000M 10.61M
Cash flows other operating - 3.37M -0.87500M -3.42400M -6.79200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 1.43M 44.92M -10.35600M 10.56M
Change in working capital 6.02M -0.05700M -5.35700M -4.68700M 3.93M
Stock based compensation 42.44M 42.93M 33.54M 29.31M 23.75M
Other non cash items 1.38M 5.09M 1.45M -1.73800M -1.72100M
Free cash flow 119.91M 167.42M 150.73M 135.03M 115.37M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CORT
Corcept Therapeutics Incorporated		 -0.45 1.32% 33.54 26.12 71.43 5.06 4.82 4.30 18.90
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

149 Commonwealth Drive, Menlo Park, CA, United States, 94025

Key Executives

Name Title Year Born
Dr. Joseph K. Belanoff M.D. Co-Founder, Pres, CEO & Director 1957
Mr. Atabak Mokari CFO & Treasurer 1977
Dr. Hazel Hunt Ph.D. Chief Scientific Officer 1960
Mr. Sean Maduck Pres of Corcept Endocrinology 1977
Mr. Gary Charles Robb Chief Bus. Officer & Sec. 1963
Mr. Joseph Douglas Lyon Chief Accounting Officer 1979
Ms. Amy Flood Chief HR & Communications Officer NA
Dr. William Guyer Pharm.D. Chief Devel. Officer 1968
Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director 1957
Mr. Sean Maduck President of Endocrinology 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.